236 related articles for article (PubMed ID: 27635473)
1. Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers.
Borrie AE; Kim RB
Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):149-156. PubMed ID: 27635473
[TBL] [Abstract][Full Text] [Related]
2. [Aromatase inhibitors and arthralgia].
Nagykálnai T; Landherr L; Mészáros E
Magy Onkol; 2011 Mar; 55(1):32-9. PubMed ID: 21617789
[TBL] [Abstract][Full Text] [Related]
3. Aromatase inhibitor-associated arthralgia syndrome.
Burstein HJ
Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?
Moscetti L; Agnese Fabbri M; Sperduti I; Fabrizio N; Frittelli P; Massari A; Pompei L; D'Auria G; Pofi E; Ruggeri EM
Tumori; 2015; 101(5):469-73. PubMed ID: 26108239
[TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations.
Coleman RE; Bolten WW; Lansdown M; Dale S; Jackisch C; Merkel D; Maass N; Hadji P
Cancer Treat Rev; 2008 May; 34(3):275-82. PubMed ID: 18082328
[TBL] [Abstract][Full Text] [Related]
6. Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort.
Castel LD; Hartmann KE; Mayer IA; Saville BR; Alvarez J; Boomershine CS; Abramson VG; Chakravarthy AB; Friedman DL; Cella DF
Cancer; 2013 Jul; 119(13):2375-82. PubMed ID: 23575918
[TBL] [Abstract][Full Text] [Related]
7. Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.
Brier MJ; Chambless DL; Chen J; Mao JJ
Eur J Cancer; 2018 Mar; 91():145-152. PubMed ID: 29329697
[TBL] [Abstract][Full Text] [Related]
8. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
[TBL] [Abstract][Full Text] [Related]
9. The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.
Liu X; Low SK; Boddy AV
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):851-63. PubMed ID: 27253864
[TBL] [Abstract][Full Text] [Related]
10. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
Lintermans A; Van Asten K; Jongen L; Van Brussel T; Laenen A; Verhaeghe J; Vanderschueren D; Lambrechts D; Neven P
Eur J Cancer; 2016 Mar; 56():31-36. PubMed ID: 26798969
[TBL] [Abstract][Full Text] [Related]
11. Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors.
Swenson KK; Nissen MJ; Henly SJ; Maybon L; Pupkes J; Zwicky K; Tsai ML; Shapiro AC
Oncol Nurs Forum; 2013 Nov; 40(6):549-57. PubMed ID: 24161633
[TBL] [Abstract][Full Text] [Related]
12. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
13. Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm.
Reinbolt RE; Sonis S; Timmers CD; Fernández-Martínez JL; Cernea A; de Andrés-Galiana EJ; Hashemi S; Miller K; Pilarski R; Lustberg MB
Cancer Med; 2018 Jan; 7(1):240-253. PubMed ID: 29168353
[TBL] [Abstract][Full Text] [Related]
14. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors.
Mao JJ; Stricker C; Bruner D; Xie S; Bowman MA; Farrar JT; Greene BT; DeMichele A
Cancer; 2009 Aug; 115(16):3631-9. PubMed ID: 19517460
[TBL] [Abstract][Full Text] [Related]
15. Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management.
Henry NL; Giles JT; Stearns V
Oncology (Williston Park); 2008 Nov; 22(12):1401-8. PubMed ID: 19086600
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitor-induced arthralgia: a review.
Niravath P
Ann Oncol; 2013 Jun; 24(6):1443-9. PubMed ID: 23471104
[TBL] [Abstract][Full Text] [Related]
17. Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?
Din OS; Dodwell D; Wakefield RJ; Coleman RE
Breast Cancer Res Treat; 2010 Apr; 120(3):525-38. PubMed ID: 20157776
[TBL] [Abstract][Full Text] [Related]
18. Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study.
Garcia-Giralt N; Rodríguez-Sanz M; Prieto-Alhambra D; Servitja S; Torres-Del Pliego E; Balcells S; Albanell J; Grinberg D; Diez-Perez A; Tusquets I; Nogués X
Breast Cancer Res Treat; 2013 Jul; 140(2):385-95. PubMed ID: 23868189
[TBL] [Abstract][Full Text] [Related]
19. Online discussion of drug side effects and discontinuation among breast cancer survivors.
Mao JJ; Chung A; Benton A; Hill S; Ungar L; Leonard CE; Hennessy S; Holmes JH
Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):256-62. PubMed ID: 23322591
[TBL] [Abstract][Full Text] [Related]
20. Safety of aromatase inhibitor therapy in breast cancer.
Lintermans A; Neven P
Expert Opin Drug Saf; 2015 Aug; 14(8):1201-11. PubMed ID: 26059833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
